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Abstract
Background: Mutations in TP53 are common events during carcinogenesis. In addition to gene mutations, several 
reports have focused on TP53 polymorphisms as risk factors for malignant disease. Many studies have highlighted that 
the status of the TP53 codon 72 polymorphism could influence cancer susceptibility. However, the results have been 
inconsistent and various methodological features can contribute to departures from Hardy-Weinberg equilibrium, a 
condition that may influence the disease risk estimates. The most widely accepted method of detecting genotyping 
error is to confirm genotypes by sequencing and/or via a separate method.
Results: We developed two new genotyping methods for TP53 codon 72 polymorphism detection: Denaturing High 
Performance Liquid Chromatography (DHPLC) and Dot Blot hybridization. These methods were compared with 
Restriction Fragment Length Polymorphism (RFLP) using two different restriction enzymes. We observed high 
agreement among all methodologies assayed. Dot-blot hybridization and DHPLC results were more highly concordant 
with each other than when either of these methods was compared with RFLP.
Conclusions: Although variations may occur, our results indicate that DHPLC and Dot Blot hybridization can be used as 
reliable screening methods for TP53 codon 72 polymorphism detection, especially in molecular epidemiologic studies, 
where high throughput methodologies are required.
Background
The tumour suppressor protein p53 is a key transcription
factor that participates in numerous homeostatic func-
tions such as cell cycle checkpoint control, repair of DNA
damage and apoptosis induction [1]. Tumour-associated
mutations in TP53, typically single nucleotide substitu-
tions in the coding sequence, are a hallmark of most
human cancers and cause dramatic defects in p53 func-
tion [2]. By contrast, only a small fraction of the naturally
occurring sequence variations (single nucleotide poly-
morphisms, SNP) of TP53  in human populations are
expected to cause measurable perturbation of p53 func-
tion [3]. The best studied TP53 SNP is on codon 72. In
human populations, codon 72 of TP53  has either the
sequence CCC, which encodes proline, or CGC, which
encodes arginine. TP53 codon 72 polymorphism alters
the ability of the p53 protein to induce apoptosis, influ-
ences the behaviour of mutant p53 and decreases DNA
repair capacity [4-6].
The role of this polymorphism in carcinogenesis has
been well studied but is a matter of controversy. A decade
ago, a dramatic effect of the TP53 codon 72 polymor-
phism on the risk of cervical cancer was reported. This
effect was explained by the finding that the E6 oncopro-
tein from high-risk mucosal human papillomaviruses
(HPVs) causes more efficient degradation of the Arg form
of the p53 protein than of the Pro form, thus reducing
cellular levels of p53 protein and increasing the risk of
HPV-associated cancers in TP53-Arg homozygotes [7].
This sparked an intensive investigation into the potential
effect of TP53 codon 72 polymorphism on susceptibility
to cervical cancer or cancer-related phenotypes. Many of
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these studies have reported significant associations.
However, the inconsistency in findings suggests that
results should be interpreted with caution. For cervical
cancer, a meta-regression analysis identified that the
most important factor contributing to heterogeneity
among results for invasive lesions was departure from
Hardy-Weinberg equilibrium in the control group. How-
ever, various methodological features can contribute to
departures from Hardy-Weinberg equilibrium and conse-
quently to less than ideal circumstances for the examina-
tion of this polymorphism [8]. Therefore, confirming
genotype results with a second method can reduce mis-
classification of genotype [9]. In doing so, deviations from
Hardy-Weinberg equilibrium can be avoided. With this
objective in mind, we aimed to compare different meth-
odologies to define reference-quality methods for TP53
codon 72 genotyping. We developed two new methods
for TP53 codon 72 polymorphism detection: Denaturing
High Performance Liquid Chromatography (DHPLC)
and Dot Blot hybridization. These methods were com-
pared with Restriction Fragment Length Polymorphism
(RFLP), a well establish method for TP53 codon 72 poly-
morphism genotyping, using two different restriction
enzymes. We report herein the findings obtained with the
validation of these methods and propose that they could
be used for TP53 codon 72 polymorphism detection in
molecular epidemiologic studies.
Results
Using a combination of both PCR strategies described
above we were able to amplify TP53 exon 4 of 962 sam-
ples, approximately 98.3% of all subjects tested. Samples
were submitted to TP53 codon 72 genotyping using four
different methods: DHPLC, Dot Blot hybridization and
RFLP using two different restriction enzymes(BsaJI and
BstUI).
DHPLC analysis of TP53  exon 4 at 59°C revealed a
small shoulder only in heterozygous samples. The first
assessment allowed the distinction of homozygous and
heterozygous samples, as illustrated in Figure 1B. We
were able to identify that 428 samples (44.5%) were
heterozygous for TP53 codon 72 polymorphism. The sec-
ond assessment which included a previously known PCR
product in the assays revealed that 377 (39.2%) of samples
were homozygous Arg/Arg and 157 (16.3%) were
homozygous Pro/Pro (Table 1). Once the same profile
was observed, we concluded that samples with the same
genotype of the PCR product added presented a single
peak, while samples with a different genotype of this
added product presented a small shoulder, indicating het-
eroduplex formation.
Using Dot-blot hybridization we observed that 418
samples (43.4%) were heterozygous for TP53 codon 72
polymorphism (Table 1). The hybridization patterns
observed both for heterozygous and homozygous sam-
ples are shown in Figure 1C. Homozygous Arg/Arg repre-
sented 374 (38.9%) samples while homozygous Pro/Pro
represented 170 (17.7%) of all samples tested.
TP53  exon 4 was also subjected to RFLP using the
restriction enzymes BsaJI and BstUI. For both enzymes a
unique digestion profile is obtained when TP53 exon 4
alleles codes for proline or arginine. BsaJI leads to genera-
tion of five fragments when TP53 codon 72 encodes the
amino acid proline (94, 66, 44, 41 and 34 base pairs).
However, only four fragments are obtained when TP53
codon 72 encodes the amino acid arginine (138, 66, 41
and 34 base pairs). Heterozygous forms present a diges-
tion profile representative of both alleles (Figure 1D).
BstUI leads to generation of two fragments when TP53
codon 72 encodes for arginine (160 and 119 base pairs).
However, this enzyme is not able to cleave TP53 encoding
homozygous proline in the codon 72. Heterozygous
forms present a digestion profile representative of both
alleles (Figure 1E).
Using BsaJI we observed that 437 samples (45.4%) were
heterozygous for TP53 codon 72 polymorphism (Table
1). Homozygous Arg/Arg represented 375 (39%) samples
while homozygous Pro/Pro represented 150 (15.6%) of all
samples tested. Using BstUI we identify 462 (48%)
heterozygous samples. A total of 319 (33.2%) were geno-
typed as homozygous Arg/Arg and 181 (18.8%) were gen-
otyped as homozygous Pro/Pro (Table 1).
The agreement between methods is summarized in
table 2. We observed high agreement in all combinations
tested. Dot-blot hybridization and DHPLC results were
more highly concordant with each other (kappa coeffi-
cient 0.92). Of the total of 962 samples analyzed, only 43
(4.5%) presented discordant results. The higher discor-
dance was observed between DHPLC and RFLP using
BstUI (kappa coefficient 0.83). We observed disagree-
ment between 102 samples, approximately 10% of all
samples tested. The comparison between RFLP using
BstUI with all methods tested revealed that this enzyme
may lead to misclassification. However, this disagreement
was not sufficient to lead to departure from Hardy-Wein-
berg equilibrium. With all methods tested, the majority of
samples were genotyped as heterozygous, followed by a
high percentage of homozygous arginine and a lower per-
centage of homozygous proline.
Discussion
Traditional studies that investigated individual TP53
polymorphisms in case-control studies of limited size
have not given definitive answers and new approaches are
required. High-throughput methodologies and consor-
tium studies investigating large number of individuals
may provide the robustness these investigations require
while minimizing genotyping errors [3].Rabachini et al. BMC Genetics 2010, 11:44
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Figure 1 p53 codon 72 genotyping. (A) PCR for TP53 exon 4 detection. PCR products were loaded on 1.5% agarose gel. 100 base pairs DNA ladder 
(lane 1), positive controls (lane 2 and 3), negative controls (lanes 4 and 26), samples tested (lanes 5-25). (B) Detection of TP53 codon 72 polymorphism 
by DHPLC. Elution profiles obtained at 59°C. Representative heterozygous (a) and homozygous profile (b and c) are depicted. Note the small shoulder 
only in heterozygous samples. After the first trial, homozygous samples were mixed in approximately equimolar proportions with a control sample 
with TP53 codon 72 polymorphism previously identified as homozygous proline. This allowed differentiating the two homozygous genotypes. Ho-
mozygous profiles represent a sample with the genotype similar to the control sample added. Heterozygous profile represents a sample with the gen-
otype differing from the control sample. (C) Dot Blot hybridization for TP53 codon 72 polymorphism genotyping. Samples were spotted onto nylon 
membranes and hybridized with biotin-labelled oligonucleotide probes for allele Arg (PArg) and allele Pro (PPro). Sample 1A, 1B and 2A represent 
positive controls. The profile observed in sample 1A is compatible with a homozygous arginine. Sample 1B presents a profile compatible with the 
genotype homozygous proline. Sample 2A presents a profile compatible with the heterozygous genotype. (D) Silver-stained 8% polyacrylamide gel 
showing the restriction profiles obtained with enzyme BstUI of the TP53 exon 4 PCR product. 50 base pairs DNA ladder (lane 1). Lanes 2, 4, 5 represent 
heterozygous samples where fragments of 279, 160 and 119 base pairs can be detected. Lanes 3 and 8 represent homozygous proline samples in 
which the enzyme was not able to digest the PCR product. Lanes 6 represent an homozygous arginine in which fragments of 160 and 119 base pairs 
can be identified. Lanes 7, 9 and 10 represent positive controls for homozygous arginine, homozygous proline and heterozygous samples, respective-
ly. (E) Silver-stained 12% polyacrylamide gel showing the restriction profiles obtained with enzyme BsaJI of the TP53 exon 4 PCR product. 50 base pairs 
DNA ladder (lane 1). Lanes 3, 4, 5 represent heterozygous samples in which fragments of 138, 94, 66, 44, 41 and 34 base pairs can be detected. Lanes 
7 represent a homozygous proline sample in which fragments of 94, 66, 44, 41 and 34 base pairs can be identified. Lanes 2, 6, 8, 10 and 11 represent 
homozygous arginine samples in which fragments of 138, 66, 41 and 34 base pairs can be detected. Lanes 9, 12 and 13 represent positive controls for 
heterozygous, homozygous arginine and homozygous proline samples, respectively.
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For cervical cancer, a meta-analysis identified that the
most important factor contributing to heterogeneity
among results for invasive lesions was departure from
Hardy-Weinberg equilibrium in the control group [8].
According to these authors, various methodological fea-
tures can contribute to departures from Hardy-Weinberg
equilibrium and consequently to less than ideal circum-
stances for the examination of this polymorphism. To
avoid these pitfalls, confirming genotype results with a
second method can significantly reduce genotyping mis-
classification [9].
The results presented in this report indicate that
DHPLC and Dot Blot can be used as reliable methods to
identify TP53 codon 72 polymorphism. The comparison
between these methods and RFLP, a well established
methodology, indicate that Dot-blot and DHPLC results
are more highly concordant with each other than when
either of these methods was compared with RFLP only.
R F L P  a n a l y s i s  w a s  o n e  o f  t h e  f i r s t  t e c h n i q u e s  t o  b e
widely used for detecting variation at the DNA sequence
level [10]. The principle behind the technology rests on
the possibility of comparing band profiles generated after
restriction enzyme digestion in DNA molecules of differ-
ent individuals. Diverse restriction sites that might have
occurred affect DNA molecules in different ways, pro-
ducing fragments of variable lengths. These differences in
fragment lengths can be seen after gel electrophoresis
[11]. However, several conditions need to be optimized in
order to achieve the high sensitivity (the amount of DNA,
the time for complete digestion, acrylamide concentra-
tion, etc). Additionally, if the DNA fragment is only par-
tially digested the interpretation of band patterns may
lead to misclassification. Compared with RFLP, dot-blot
hybridization can be considered a moderately demanding
technique. However, Dot blot is much less time consum-
ing since a large number of samples can be hybridized on
a single membrane. On the other hand, DHPLC can be
considered a quick and easy screening method. This
method allows the identification of mutations and poly-
morphisms based on detection of heteroduplex forma-
tion between mismatched nucleotides in double stranded
PCR amplified DNA. Sequence variation creates a mixed
population of heteroduplexes and homoduplexes during
reannealing of heterozygous and homozygous DNA.
When this mixed population is analyzed by HPLC under
partially denaturing temperatures, the heteroduplexes
elute from the column earlier than the homoduplexes
because of their reduced melting temperature [12]. Thus,
the sensitivity of this method is dependent on the tem-
perature at which the analysis is completed. For the anal-
ysis of TP53 codon 72 polymorphism we have relied on
the software-based predictions and we also selected over-
lapping temperatures to increase the chance of heterodu-
plex detection. Although we have not detected any false
negative or false positive cases using DHPLC and Dot
Blot, it is advisable to sequence a small percentage of ran-
Table 1: Frequencies of TP53 codon 72 genotypes for 962 women who were tested by 4 methods
Typing method Genotype frequencies (%)
Arg/Arg Pro/Arg Pro/Pro
DHPLC 377 (39.2) 428 (44.5) 157 (16.3)
Dot Blot 374 (38.9) 418 (43.4) 170 (17.7)
RFLP- BsaJI 375 (39.0) 437 (45.4) 150 (15.6)
RFLP-BstUI 319 (33.2) 462 (48.0) 181 (18.8)
Table 2: Inter-method variation in TP53 genotyping
Typing method Frequency of joint distribution (%) Weighted Kappa Coefficient
Agreement Disagreement
DHPLC × Dot Blot 919 (95.5) 43 (4.5) 0.92
DHPLC × BsaJI 887 (92.2) 75 (7.8) 0.88
DHPLC × BstUI 860 (89.4) 102 (10.6) 0.83
Dot Blot × BsaJI 895 (93.0) 67 (7.0) 0.90
Dot Blot × BstUI 864 (89.8) 98 (10.2) 0.85
BsaJI × BstUI 869 (90.3) 93 (9.7) 0.85Rabachini et al. BMC Genetics 2010, 11:44
http://www.biomedcentral.com/1471-2156/11/44
Page 5 of 7
domly selected samples as a standard procedure for qual-
ity control purposes.
The high concordance between DHPLC and Dot Blot
reveal that both methodologies are sensitive, reliable, fast
and reproducible. Our results demonstrate that these
methods can be used in combination with each other or
in combination with RFLPBsaJI and RFLP-BstUI to spe-
cifically detect TP53 codon 72 polymorphism. Even with
some level of disagreement, observed when RFLP-BstUI
was used as genotyping method, we did not observe
departure from Hardy-Weinberg equilibrium, one of the
most important factors contributing to disagreement
observed in the literature.
Conclusions
Because TP53 codon 72 polymorphism has been associ-
ated with cancer susceptibility, prognosis, response to
treatment, and even survival it is of fundamental impor-
tance to efficiently and accurately detect this polymor-
phism in biological specimens. The use of appropriate
methods may have a remarkable importance for defining
the real role of TP53 codon 72 polymorphism in many
types of human neoplasias.
Methods
Samples
We tested for TP53 codon 72 polymorphism specimens
from a sub-cohort of 978 Brazilian women enrolled in the
Ludwig-McGill cohort study [13]. The Ludwig-McGill
Cohort Study is an ongoing investigation of the natural
history of HPV infection and the risk of cervical neopla-
sia. This study adhered to the tenets of the Declaration of
Helsinki. All participants entered the study only after giv-
ing signed informed consent. All study procedures and
the informed consent were approved by the institutional
review boards and ethical committees of the Ludwig
Institute for Cancer Research and the Maternidade
Escola Vila Nova Cachoeirinha clinic, both in São Paulo,
Brazil [13]. DNA was extracted from exfoliated cervical
cells and purified by spin column chromatography. Four
different methodologies were used to detect TP53 codon
72 polymorphism: DHPLC, RFLP using two different
restriction enzymes - BstUI and BsaJI and Dot-blot
hybridization. Because TP53 codon 72 polymorphism is
located at TP53  exon 4, previous amplification of this
region was performed. The resultant amplicon was then
tested by the methodologies described below.
Amplification of TP53 exon 4
To establish and optimize TP53 codon 72 genotyping we
performed a previous amplification of TP53 exon 4. Since
this exon encodes a polyproline domain [14] GC-rich
regions are frequently found. This condition favoured the
generation of primer-dimers during amplification leading
to low yield of PCR product. To avoid this problem we
used hot start PCR to increase specificity [15]. In addi-
tion, because optimal primers annealing temperatures
differ for more than 6°C we also used touchdown PCR to
prevent non-specific extensions. The combination of
both PCR strategies improved the yield of amplification
and a single fragment of 279 base pairs was obtained (Fig-
ure 1A). The total reaction volume for DNA amplification
was 50 μL. Each reaction was carried out using 0.5 μM of
each of the two primers: TP53  +, 5'-TCCCCCTTGC-
CGTCCCAAG-3'; and TP53 -, 5'-CGTGCAAGTCACA-
GACTT-3'; in a mixture containing 10 mM Tris-HCl (pH
8.5), 50 mM KCl, 1.5 mM MgCl2, 200 mM of each
deoxiribonucleotides, and 2 U of Taq Gold DNA Poly-
merase (Applied Biosystems -- Roche, New Jersey, NY).
All other reagents were purchased from GIBCO BRL
(Gaithersburg, MD). One microliter of DNA was added
to the reaction. A negative control containing no DNA
was also included with each series of reactions to check
for contamination. For controls, we included 50 ng of
DNA from SW756 cells and from a penile condyloma,
known to be heterozygous and homozygous TP53 -Pro in
codon 72, respectively. Reactions were conducted in a
TC-341 thermal controller (Amersham Pharmacia Bio-
tech, Buckinghamshire, England) with the following
amplification profile: The following amplification profile
was employed: 95°C for 10 min, 10 cycles of 95°C for 1
min, 58°C for 1 min and 72°C for 1 min followed by 15
cycles of 95°C for 1 min, 56°C for 1 min and 72°C for 1
min and an additional round of 15 cycles of 95°C for 1
min, 53°C for 1 min and 72°C for 1 min. A final extension
step was added including 72°C for 3 min followed by 95°C
for 10 min. Amplification products were run on 1.5% aga-
rose gels containing 3 mg/ml of ethidium bromide at 90--
100 V for 20--30 min. Bands were visualized and photo-
graphed on a UV transilluminator. Positive reactions
were selected for TP53 codon 72 polymorphism detec-
tion.
Denaturing HPLC Analysis (DHPLC)
PCR products were heated at 95°C for 10 min and
allowed to cool down to room temperature for approxi-
mately 30 min. Five to 10 μL of each sample were run on a
Wave DNA Fragment Analysis System (Transgenomic,
Omaha, NE) using a DNASep column and the run was
monitored by ultraviolet light (UV) (260 nm). Optimum
DHPLC temperatures were determined by an incremen-
tal temperature scan, using the software-predicted melt-
ing profile as a starting point (Transgenomic, Omaha,
NE). Samples were run at more than one temperature due
to the heterogeneity in the distribution of GC-rich
regions that results in a heterogeneous melting tempera-
ture distribution throughout the amplified DNA frag-
ments to be analyzed. By using 59°C as a meltingRabachini et al. BMC Genetics 2010, 11:44
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temperature we were able to identify the formation of
heteroduplexes in a subset of samples submitted to the
analysis. The heteroduplexes are frequently found in
samples with differences in alleles. Thus, heterozygous
samples were identified due to a small shoulder peak in
the chromatogram. After distinguishing the heterozygous
samples, the subset of homozygous samples were mixed
in approximately equimolar proportions with a control
sample with TP53  codon 72 polymorphism previously
i d e n t i f i e d  a s  h o m o z y g o u s  p r o l i n e .  T h i s  m i x t u r e  w a s
heated at 95°C for 10 min and allowed to cool down to
room temperature for approximately 30 min. Five to 10
μL of each sample were then submitted to a new DHPLC
analysis. This allowed differentiating the two homozy-
gous genotypes. Heteroduplexes were observed in sam-
ples with genotype homozygous arginine, since the PCR
product added to the sample was known to be homozy-
gous proline. The homoduplexes, or samples with a single
peak, were observed in samples with genotype proline,
since it was the same genotype presented by the control
sample added to the mixture. As an additional control,
10% of the samples were randomly selected and mixed
with the same equimolar proportions of a control sample
previously identified as homozygous arginine. Results
were compared and no discordant results were observed
between the two pulled analyses.
Dot Blot Hybridization
After amplification of TP53 gene exon 4, 1.5 μL of PCR
products were spotted on nylon membranes (Hybond N+
- Amersham Pharmacia Biotech, Buckinghamshire, Eng-
land) and UV-cross-linked. Dot-blotted PCR products
were hybridized with sequence-specific 3'; biotin-labelled
oligonucleotide probes TP53 Arg 5'--GGGCCACGCG-
GGGAGCA-3' and TP53 Pro 5'--GGGCCACGGGGG-
GAGCA- 3'. Hybridization was performed in two
different temperatures: 62°C for TP53 Arg and 64°C for
TP53 Pro probe. Briefly, membranes were blocked with
15 ml 0.1 × SSPE (18 mM NaCl; 1 mM NaH2PO4-H2O;
0.55 mM NaOH; 0.1 mM EDTA; adjusted for pH 7,4),
0.5% SDS for 20 min and then pre-hybridized with 15 ml
of 2 × SSPE (360 mM NaCl; 20 mM NaH2PO4-H2O; 11
mM NaOH; 2 mM EDTA; adjusted for pH 7,4), 0.1% SDS
for 20 min. All steps above were performed in probe-spe-
cific hybridization temperature. Probes were added to
pre-hybridization solution to a final concentration of 1.2
pmoles/mL. After overnight hybridization, membranes
were washed 2 times of 15 min with 2 × SSPE, SDS 0.1%
in hybridization temperature. Incubation with conjugated
horseradish peroxidase-streptavidin (1 mg/mL; Vector
Laboratories, Burlingame, CA, USA) was performed in
room temperature. Membranes were washed 2 times
with 2 × SSPE, SDS 0.1% for 10 min to eliminate back-
ground and minimize misclassification. Positive reactions
were detected by enhanced chemiluminescence (ECL Kit,
Amersham) through exposure to Kodak X-OMAT film
(Kodak, Rochester, NY). If needed to obtain optimal sig-
nal intensities, the exposure times were sometimes var-
ied, as judged by evaluation of the hybridization controls
present on each membrane.
Restriction Fragment Length Polymorphism (RFLP)
After TP53 exon 4 amplification, 7 μL of the amplified
reaction products were digested in a 10 μL volume of 1 ×
NEB buffer 2 and 5 U of BsaJI or BstUI endonucleases
(New England BioLabs, Newton, MA) at 60°C for at least
2 hours. Products digested by BsaJI were run in 12% poly-
acrylamide gel and products digested by BstUI were run
in 8% polyacrylamide gel. In both cases silver staining was
used to identify band profile [16].
To ensure quality control of all genotyping methods,
the samples were blindly read by two persons indepen-
dently (TR, LLV). Despite the high percentage of agree-
ment, around 95% for each method, the samples with
discordant results were submitted to a new round of
amplification and genotyping.
Statistical Analysis
Cohen's kappa coefficients of agreement were computed
to evaluate the inter-methodology variability in genotyp-
ing.
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